What happened
The International Coalition of Medicines Regulatory Authorities (ICMRA) is holding its summit and general assembly in Seoul from November 3 to 6, 2026. Hosted by South Korea’s Ministry of Food and Drug Safety, the event brings together leaders from 43 regulatory agencies across 40 countries, including the EMA and Japan’s PMDA. A central focus of the summit is the development of international standards for AI in drug regulation and the implementation of new approach methodologies (NAMs) to replace traditional animal testing.
The ICMRA summit, held at Conrad Seoul, marks the first time the event has been hosted in South Korea since the country became a founding member in 2013. The agenda is structured across four days, featuring an executive committee meeting, a high-level summit, and a general assembly.
The summit’s primary agenda focuses on the practical utilization of AI in drug regulation. This includes defining how regulators should evaluate AI models used in drug discovery and clinical trials, as well as the integration of new approach methodologies (NAMs) like organoids to reduce reliance on animal testing.
South Korea’s Ministry of Food and Drug Safety is co-chairing the AI session alongside Singapore’s Health Sciences Authority. This session continues the work of the AIRIS initiative, which previously collaborated with the U.S. FDA and the WHO to address the safety and regulatory challenges posed by AI-based medical products.
Source details: biz.chosun.com
Why it matters
As AI-driven drug discovery and medical product development accelerate, the lack of harmonized global regulations creates significant barriers for pharmaceutical companies seeking international market entry. By co-chairing the AI regulation session—branded as the International Artificial Intelligence Regulatory Industry Symposium (AIRIS) 2026—South Korea is positioning itself to influence the global standards that will govern how AI-based medical products are validated and approved. This summit aims to move beyond theoretical discussions toward practical, cross-border cooperation, such as joint reviews and data sharing, which could streamline the approval process for innovative AI-developed therapies.
The current regulatory landscape for AI in medicine is highly fragmented, with different countries applying varying standards for safety and efficacy. This creates a 'regulatory bottleneck' for biotech firms that must navigate distinct approval processes for each market.
By facilitating discussions on joint reviews and information exchange, the ICMRA summit aims to reduce these redundancies. If successful, these efforts could significantly lower the cost and time required for AI-driven drug development, ultimately benefiting patients by accelerating access to new treatments.
The involvement of major regulators like the EMA and PMDA suggests that the standards discussed in Seoul will likely form the basis for future international guidelines, making this a critical event for the global pharmaceutical industry.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
Why can ethical evaluation not be reduced to one model score?
What to watch next
Observers should monitor the outcomes of the AI regulation session and the subsequent bilateral agreements between the Ministry of Food and Drug Safety and agencies like the EMA and Australia’s TGA. Specifically, look for concrete commitments regarding the harmonization of AI validation protocols and the adoption of NAMs. These agreements will signal whether global regulators are moving toward a unified framework for AI-based medical products or if regional fragmentation will persist, impacting the speed at which AI-developed drugs reach patients globally.
Watch for official statements regarding the 'practical cooperation foundation' mentioned by the Ministry of Food and Drug Safety. Specifically, look for details on whether participating nations agree to mutual recognition of AI-based safety data.
The transition from the 2024 and 2025 AIRIS symposiums to this year's summit indicates a shift toward implementation. Future updates will likely reveal whether these discussions result in binding international protocols or remain as non-binding guidance documents.
Monitor the impact of these regulatory discussions on domestic pharmaceutical and biotech companies, as the Ministry of Food and Drug Safety explicitly stated that the summit is intended to support these firms in entering global markets.